147245-92-9
147245-92-9 structure
- Name: Glatiramer acetate
- Chemical Name: acetic acid,(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid,(2S)-2-aminopentanedioic acid,(2S)-2-aminopropanoic acid,(2S)-2,6-diaminohexanoic acid
- CAS Number: 147245-92-9
- Molecular Formula: (C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2)x.xC2H4O2
- Molecular Weight: 623.65000
- Catalog: Biochemical Peptide
- Create Date: 2018-02-16 08:00:00
- Modify Date: 2026-07-24 13:49:43
-
Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression[1][2][3].
| Name | acetic acid,(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid,(2S)-2-aminopentanedioic acid,(2S)-2-aminopropanoic acid,(2S)-2,6-diaminohexanoic acid |
|---|---|
| Synonyms |
MFCD04113403
Copolymer 1 Phmaceutical Glatiramer acetate L-Alanine polyMer with L-GlutaMic Acid L-Lysine L-Tyrosine Acetate UNII-5M691HL4BO GlatiraMer-d7 Glatiramer acetate [USAN:BAN] L-GlutaMic Acid ptide with L-Alanine L-Lysine L-Tyrosine Acetate Salt Glatiramer acetate API Glatiramer acetate - Bio-X GaltiraMer acetate GLATIRAMER ACETATE l-glutamic acid polymer with l-alanine, l-lysine and l-tyrosine, acetate (salt) Copaxone Glatyramer acetate COP-1 l-alanine compound with l-glutamic acid and l-lysine and l-tyrosine and acetic acid (1:1:1:1:1) Glatirameracetat Glatiramer acetate //BP ProtiraMer 511: PN: WO2010103292 PAGE: 64 claiMed sequence Chloramine B -6 aceticacid,(2S)-2-amino-3-(4-hydroxyphenyl)propanoicacid,(2S)-2-aminopentanedioicacid,(2S)-2-aminopropanoicacid,(2S)-2,6-diaminohexanoicaci L-Tyrosine polyMer with L-Alanine L-GlutaMic Acid L-Lysine Acetate |
| Description | Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Glatiramer acetate (25-100 mg/kg; S.c; 5 days) increase BDNF levels[3]. In huntington’s disease (HD) mouse model, the N171-82Q transgenic mouse line, which exhibits a more rapidly progressing disease course. Glatiramer acetate (1 mg/mouse; s.c.; 5×week) beginning at 8 weeks of age and continuing until 20 weeks of age, which is near the age of death due to the disease. Glatiramer acetate elicited improves performance on several motor function measures. Glatiramer acetate significantly improves the performance of N171-82Q transgenic mice at 15 weeks of age in the rotarod test measured over the course of 4 days[3]. |
| References |
| Boiling Point | 385.2ºC at 760mmHg |
|---|---|
| Melting Point | >239°C (dec.) (lit.) |
| Molecular Formula | (C9H11NO3.C6H14N2O2.C5H9NO4.C3H7NO2)x.xC2H4O2 |
| Molecular Weight | 623.65000 |
| Flash Point | 186.7ºC |
| Exact Mass | 623.30100 |
| PSA | 374.13000 |
| LogP | 2.14760 |
| Vapour Pressure | 1.27E-06mmHg at 25°C |
| Storage condition | 2-8°C |